EU Says Yes to Mylotarg for AML, No to Adjuvant Sunitinib EU Says Yes to Mylotarg for AML, No to Adjuvant Sunitinib
Gemtuzumab ozogamicin (Mylotarg) has been recommended for approval in Europe for use in acute myeloid leukemia, but adjuvant sunitinib after kidney cancer surgery was turned down.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Health | Hematology | Kidney Cancer | Leukemia | Urology & Nephrology